StockNews.AI
ANAB
StockNews.AI
197 days

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

1. AnaptysBio to receive $15 million and 10% royalties for imsidolimab. 2. Vanda's imsidolimab shows strong Phase 3 results for Generalized Pustular Psoriasis.

3m saved
Insight
Article

FAQ

Why Bullish?

The licensing agreement and royalties enhance ANAB's revenue potential, similar to past successful partnerships boosting stock prices.

How important is it?

The significant financial terms and future revenue from imsidolimab make this highly relevant for ANAB's valuation.

Why Long Term?

The ongoing commercialization of imsidolimab could result in sustained revenue growth over several years.

Related Companies

VNDAANAB
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis Vanda expects to immediately begin preparing BLA and MAA applications for the US and EU Anaptys to receive $15 million from Vanda, comprised of a $10 million upfront payment and $5 million for existing drug supply Anaptys to receive a 10% royalty on global net sales of imsidolimab WASHINGTON and SAN DIEGO , Feb. 3, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab (IL-36R antagonist mAb), which has successfully completed two registration-enabling global Phase 3 trials, GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of imsidolimab in patients with Generalized Pustular Psoriasis (GPP). GPP is a rare skin disorder often caused by mutations in the IL36RN gene that codes for a regulatory protein that balances the activity of the proinflammatory IL-36 family of cytokines.

Related News